How effective is deuterated coxitinib tablets in treating psoriasis?

Deuterated colexitinib tablets have significant clinical efficacy in the treatment of psoriasis, and the long-term efficacy is stable.

Deuterated colexitinib tablets are a new oral small molecule targeted drug that mainly acts on the TYK2 target, which plays a very important role in the core pathogenic pathway of psoriasis - the IL-23/Th17 axis. By inhibiting TYK2, deuterated coxitinib tablets can effectively block abnormal immune signaling, thereby achieving the effect of treating psoriasis.

In multiple long-term extension trials, deuterated colexitinib tablets have demonstrated impressive efficacy. For example, inPOETYK In three-year follow-up data from the long-term extension trial of PSO, patients who continued treatment with deuterocelexitinib and whose Psoriasis Area and Severity Index (PASI) improved by at least 75% maintained a clinical response rate of 73.2%. In addition, PASI The response rates for 90and static physician global assessment (sPGA)0/1 were 48.1% and 54.1% respectively. These data demonstrate the excellent performance of deuterated colexitinib tablets in the treatment of psoriasis.

In addition to the significant short-term efficacy, the long-term efficacy of deuterated colexitinib tablets is also very stable. Among patients who continued treatment through week 148, PASI 75The response rate remains at 73.2%, which remains stable compared with the results of 16 weeks and 52 weeks. This indicates that deuterated colexitinib tablets can provide long-term and stable efficacy for psoriasis patients.

In terms of safety, deuterated colexitinib tablets also showed good characteristics. In the long-term extension trial, the incidence of adverse events or serious adverse events did not increase with the extension of treatment time, and no new safety signals emerged. This shows that deuterated colexitinib tablets have a high safety profile in the treatment of psoriasis.

As an oral drug, deuterated colexitinib tablets are more convenient than injectable biologics. Patients do not need to frequently go to the hospital for injection treatments and can take their own medicines at home, which greatly improves patients' compliance and quality of life.

Psoriasis is a chronic disease that requires long-term treatment and management. Deuterated colexitinib tablets, as a new oral drug, provide a new treatment option for psoriasis patients. Especially for those patients who want to improve their skin lesions but are unable to have frequent follow-up visits or who are afraid of injections, deuterated colexitinib tablets are undoubtedly an option worth considering.

Compared with traditional immunosuppressants, deuterated colexitinib tablets have higher selectivity and lower incidence of side effects. Although traditional immunosuppressants can alleviate the disease to a certain extent, they are often accompanied by a greater risk of side effects. Deuterated colexitinib tablets reduce the occurrence of adverse reactions related to JAK1-3 by precisely inhibiting the TYK2 target.

Judging from the actual feedback from patients, many patients have achieved significant curative effects after taking deuterated colexitinib tablets. For example, a patient basically recovered after 13 weeks of treatment, and continued to take medication to maintain the effect. These actual cases further confirm the effectiveness of deuterated colexitinib tablets in the treatment of psoriasis.

Deuterated colexitinib tablets have shown significant efficacy and stable long-term effects in the treatment of psoriasis. Its safety and tolerability are also widely recognized.